AstraZeneca

News

EMA starts review of Enhertu for HER2+ gastric cancer

The EMA has started its review of AstraZeneca and Daiichi Sankyo's Enhertu for a second indication, as a second-line treatment for HER2-positive gastric cancer.

News

AZ/Daiichi partner with Merck on first-line lung cancer tria...

The dominance of Merck & Co's Keytruda in the treatment of previously-untreated non-small cell lung cancer (NSCLC) means it will be hard to dislodge – so AstraZeneca and Daiichi Sankyo

News

AZ's Imfinzi is first immunotherapy to raise survival in bil...

AstraZeneca's checkpoint inhibitor Imfinzi has become the first cancer immunotherapy to improve survival in previously-untreated patients with biliary tract cancer (BTC), a rare and aggress

News

Merck files pill for milder COVID, as AZ showcases its antib...

As expected, Merck & Co has moved ahead swiftly with an emergency use application for its oral antiviral molnupiravir, aiming to protect people with mild or moderate COVID-19 from devel

News

AZ files for emergency use of COVID-19 antibody combo in US

AstraZeneca has sought emergency use authorisation for its antibody combination AZD7442, following trial results indicating it can prevent symptomatic COVID-19 infection when given to healt

News

Enhertu nabs speedy FDA review for earlier use in breast can...

Hard on the heels of impressive new data for Enhertu as a second-line therapy for breast cancer, AstraZeneca and Daiichi Sankyo have claimed FDA breakthrough status for the drug that should

EMA starts review of Enhertu for HER2+ gastric cancer

AZ/Daiichi partner with Merck on first-line lung cancer tria...

AZ's Imfinzi is first immunotherapy to raise survival in bil...

Merck files pill for milder COVID, as AZ showcases its antib...

AZ files for emergency use of COVID-19 antibody combo in US

Enhertu nabs speedy FDA review for earlier use in breast can...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

AstraZeneca

Editor's Picks